Merial, Henry Schein and MAI Animal Health partnered to host the second annual Equine Gastric Health Symposium and Wet Lab prior to the 62nd AAEP Annual Convention.
“This event is held to benefit veterinarians and the horses in their care by continuing their education about equine gastric ulcers and best practices when using a gastroscope. Veterinarians in attendance were comprised of diverse practice backgrounds and scoping experience,” says Beckie Peskin, Associate Director of Equine Marketing, Merial.
“It helps veterinarians ‘click’ with the scope,” says Hoyt Cheramie, DVM, MS, Senior Manager, Large Animal Veterinary Services, Merial. “It allows them to be comfortable and confident with the process, and even how to communicate and explain the procedure and findings with the client.”
The two-part event began with seminars presented by industry experts Hoyt Cheramie on Equine Gastric Ulcer Syndrome (EGUS), and Denise Farris, Esq, on Veterinary Risk Management.
The hands-on gastroscopy wet lab portion took place at the Osceola County Fairgrounds. Four veterinary service managers from Merial led small groups of attendees through the process of how to approach scoping and successful techniques.
Each attendee was able to get hands-on experience with passing and driving the scope. A total of 12 horses were scoped, ranging in disciplines and ages. Of those 12, 10 had gastric legions ranging from mild to severe.
The event concluded with a lecture on The Value of Scoping from Dan Carter, DVM, CJF. This program was approved for Registry of Approved Continuing Education (RACE) credits.
“The goal is to equip the veterinarians with the knowledge and experience to ‘see it, do it, and then teach it’ in their practices.” Cheramie says. “Everyone was excited and engaged, making it a successful event.”
On January 1, 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales. For more information, please visit www.boehringer-ingelheim.com.
